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Abstract
Immune checkpoint inhibitors (ICIs) have been approved as first or second 
line therapy in a large group of cancers. However, the observation of potentially 
long-lasting responses was restricted to limited subset of patients. Efforts have been 
made to identify predictive factors of response to ICIs in order to select eligible 
patients and to avoid exposing non-responding patients to treatment side effects. 
Although several biomarkers have been identified, their predictive potential 
remains unsatisfactory. One promising emerging approach is to focus on dynamic 
biomarkers to directly characterize the response and, more importantly, to iden-
tify those patients presenting an immune response failure. Several studies have 
shown a strong correlation between specific circulating immune cell subsets and 
tumor immune infiltrates. Moreover, liquid biomarkers including soluble immune 
checkpoint molecules have potential in predicting the modulation of the immune 
response under immune checkpoint blockade. In this chapter, we will discuss cur-
rent advances in the study of circulatory and intra-tumoral dynamic biomarkers as 
predictors of responses to ICIs therapy in cancer.
Keywords: dynamic biomarkers, serum soluble biomarkers, cellular immune 
response, immune checkpoint inhibitors, CTLA-4, PD-1, tumor control
1. Introduction
The immune checkpoint cell surface proteins like programmed death-ligand 1 
(PD-L1), programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated pro-
tein 4 (CLTA-4) represent important pathways of cancer immune evasion. Immune 
checkpoint inhibitors (ICIs) are identified as potent key players in providing thera-
peutic benefit in a range of solid cancers as well as in a subgroup of hematological 
malignancies. However, the response rates to these immune-modulatory molecules 
are sub-optimal and predictive biomarkers allowing to select for responsive cancer 
patients are lacking. The study of the dynamics of the immune system and of the 
tumors under immune checkpoint blockade has greatly improved knowledge on the 
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mechanisms of action of ICIs, allowing the identification of a number of novel can-
didate dynamic biomarkers predictive of ICI treatment response meriting further 
exploration in validation trials.
Tumor biopsy of tissue from primary or metastatic site is a major mainstay of 
treatment decisions as the molecular features and histology can reveal the complex 
cancer landscape. However, tissue biopsy has various limitations such as high 
heterogeneity, invasive nature of tissue sampling and skilled expertise/techniques 
required for analyzing and reporting making it a difficult specimen especially for 
treatment monitoring purpose [1]. Therefore, emphasis on utility of liquid biopsies 
as prognostic and predictive soluble biomarkers especially in cancer immuno-
therapy is gaining a lot of attention. The main advantages of blood-based specimens 
are that these are easy to extract and analyze with limited skilled expertise or 
techniques. Furthermore, biomarkers in the blood can represent dynamic altera-
tions of the evolving cancer in response to treatment and can help in longitudinal 
monitoring. In addition to this, these can also be utilized for risk prediction of 
immune-related adverse events (irAE) which is an important and critical monitor-
ing parameter [2].
In this chapter, we attempt to discuss in relevant details the purpose and role of 
immune modulatory molecules and of the different serum soluble biomarkers in 
various human and animal models with an aim to show insight on to their mecha-
nisms of action and resistance, thus conveying information predictive of therapeu-
tic response.
2. Effect of immune checkpoint blockade on effector T cells
2.1 Effect of PD-1 blockade on effector T cells
PD-1 is an important immune checkpoint expressed on activated T cells and 
known to regulate their functional activity. By binding to its ligands, PD-L1 or 
PD-L2, which are expressed on tumor cells and a variety of immune cells [3], 
PD-1 is able to inhibit downstream signaling of the T cells receptor (TCR) [4]. 
Hence, ICIs targeting the PD-1/PD-L1 axis are developed to modulate this negative 
feedback loop and restore T cells activity. Indeed, response to anti PD-1 drugs is 
characterized by the upregulation of genes associated with activation of effector 
T cells [5–7]. Moreover, the blocking of PD-1 has been linked to an expansion of 
CD8+ effector T cells within the tumor. Interestingly, this CD8+ T cells expansion 
was found to follow a specific gradient that decreases from the margins of the 
tumor into its center [5, 8, 9]. In addition, the noted expansion in CD8+ T cells 
was also found to coincide with an increase in CD8+ T cell clonality in the tumor 
microenvironment (TME) [8]. This is clearly indicative of the fact that CD8+ T cells 
expanded in the tumor upon blocking PD-1 are indeed tumor-reactive and stand as 
a consistent correlate of treatment benefit.
Another interesting aspect is the heterogeneity noted in the tumor infiltrating 
CD8+ T cells depending on their different phenotypes and functional states. One 
such subset is known to express high levels of PD-1 and co-express the follow-
ing immune modulating proteins: the T-cell immunoglobulin and mucin-domain 
containing-3 (TIM-3), the lymphocyte-activation gene-3 (LAG-3), the T cell immu-
noreceptor with Ig and ITIM domains (TIGIT) and CD39, which are all linked to T 
cells exhaustion [Tex] [10, 11]. Exhausted CD8+ T cells represent a dysfunctional 
cell state that develops due to chronic antigen exposition. However, exhausted 
CD8+ T cells in the TME have a higher potential for tumor antigens recognition and 
a higher clonal distribution than any other CD8+ T cells subset in the TME [12, 13]. 
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Further, the Tex phenotype also defines an impaired capacity of producing effector 
cytokines such as IL-2, TNF-α and IFN-γ [12]. The inhibition of the PD-1/PD-L1 
axis was initially suggested to reinvigorate the anti-tumoral immune response by 
reversing the state of these terminally exhausted tumor-reactive T cells. However, 
this function is challenged by the fact that this state of terminal exhaustion is 
characterized by a distinct epigenetic profile which limits its reversibility [14–16]. 
In support of this, recent evidence has shown that anti-PD-1 therapy can engage 
progenitor Tex subsets that co-express PD-1 and the lineage-determining transcrip-
tion factor 1 (tcf-1), instead of terminally exhausted subsets [17, 18]. Similarly, 
certain studies on animal models also show that blocking PD-1 leads to the engaging 
of PD-1+/tcf-1+/CD8+ T cells inducing their self-regeneration or differentiation into 
effector tcf-1− cells that eventually develop functional states of exhaustion [19, 20]. 
Interestingly, it has been shown that Tex subsets might promote the recruitment 
of other immune cells into the TME and consequently support the anti-tumoral 
immune response [12]. In addition, anti-PD-1 treatment was shown to engage 
memory-precursor like CD8+ T cell subsets, leading to their accumulation in the 
TME [21] and to a subsequent enhanced cytotoxicity towards cancer cells [22]. 
The on-treatment increase in memory CD8+ T cells was suggested to correlate with 
response to anti-PD-1 therapy in both preclinical models and clinical studies [9, 23].
blocking of PD-1 is known to cause an increase in the proliferation of CD8+ T 
cells very early during the course of treatment [24, 25]. This proliferative response 
can be observed in the periphery, where it peaks as early as 7 days following the 
introduction of anti-PD-1 therapy [24, 26]. In one of our studies on a gastric 
cancer patient undergoing anti-PD-1 therapy, we observed that the frequency of 
peripheral cytotoxic T cells CD8+/CD107+ specific for the NY-ESO-1 cancer testis 
antigen closely correlated with the patient clinical outcome [27]. Another study 
has reported that the proliferative response of peripheral CD8+/PD-1+ T cells could 
be predictive of durable clinical benefit in patients with solid tumors receiving 
anti-PD-1 therapy [26]. Thus, these studies support the fact that the systemic CD8+ 
effector T cells response plays a key role in tumor management under anti-PD-1 
treatment and suggest their importance as a predictive biomarker of response to 
PD-1 blockade. In Figure 1 we illustrate the dynamics of intra-tumoral effector T 
cells that are shown to correlate with anti-PD-1 treatment outcome.
2.2 Effect of CTLA-4 blockade on effector T cells
When T cells are engaged in an active immune response, the expression of the 
surface protein CTLA-4, a homolog of CD28 with high affinity to B7–1 and 2 ligands, 
will be upregulated. CTLA-4: B7–1/2 binding acts as a co-inhibitor of the TCR signal 
[28]. Thus, the primary role of the CTLA-4 checkpoint is to negatively regulate T 
cell activation especially during the priming phase upon binding to the B7 ligands 
expressed by antigen presenting cells (APC). In accordance with this, a major aspect 
of anti-CTLA-4 therapy is its ability to reinvigorate T cell proliferation and activation. 
Indeed, the effects of anti-CTLA-4 therapy are evident in several studies on mouse 
models. For example, CTLA-4 deficient mice were found to display rapidly lethal 
lymphoproliferation [29]. On the other hand, anti-CTLA-4 therapy led to the expan-
sion of both CD4+ and CD8+ effector T cells in the tumor [30]. Although both T cells 
subsets are necessary in mediating tumor immune control [31], the increase in CD4+ 
T cells appeared to be of a greater importance than that of CD8+ T cells [30].
In few studies, CD8+ T cells expansion has been shown to translate into an effec-
tive response to immune checkpoint blockade therapy [7, 32]. However, a study on 
advanced melanoma patients undergoing treatment with the anti-CTLA-4 antibody 
tremelimumab, reports no association between the expansion of CD8+ effector T 
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cells and successful anti-tumor response [33] despite similar CD8+ T cells activation 
profiles observed in lesions that responded to anti-CTLA-4 therapy and those that 
did not respond to this therapy [33]. These findings, possibly explained by the action 
of immunosuppressive elements in the TME, highlight that adequate CD8+ effector T 
cells function is necessary but not sufficient for complete suppression of tumor growth 
under immunotherapy [34]. Another interesting effect noted upon CTLA-4 blockade 
is the enhanced expansion of memory CD8+ T cell [35] which will help to promote 
long-term tumor control post-therapy. Moreover, this expansion of memory CD8+ T 
cells is considered as an indicator of treatment benefit in a few clinical studies [36, 37].
CD4+ T cells expanding in the tumors of mouse models under anti-CTLA-4 
treatment are found to exhibit a Th1-like effector phenotype with a noticeable 
expression of ICOS, a known marker of follicular T helper cells [30]. Interestingly, 
this phenotype of CD4+ T cell was observed in mice after genetic knock-down of 
negative co-inhibitory molecules such as CTLA-4 [38]. Moreover, ICOS-deficient 
mice showed an impaired anti-tumor T cell response to anti-CTLA-4 therapy [39]. 
In addition, a tumor microenvironment that is rich in CD4+ Th1 effector T cells 
infiltration was shown to be critical to develop response to anti-CTLA-4 therapy 
in castration resistant prostate cancer [40]. Furthermore, a higher expression of 
Th1 associated genes was observed in melanoma tumors of patients responding to 
ipilimumab compared to non-responders, supporting the functional relevance of a 
Th1- response in CTLA-4 inhibitor treatment benefit [41]. Interestingly, while the 
presence of CD4+ Th1 cells is predictive of response to anti-CTLA-4, a peripheral 
blood profile rich in Th17 cells was reported to be rather predictive of autoimmune 
toxicity under anti-CTLA-4 therapy [42]. Moreover, several clinical studies have 
reported an increase of ICOS+/CD4+ T cells in the tumor and peripheral blood of 
patients treated with anti-CTLA-4 [43–49]. Additionally, an increased prolifera-
tion of both peripheral CD4+ and CD8+ T cells is observed as early as 3 weeks after 
the first dose of anti-CTLA-4 treatment [50–52]. Such a response may partly be 
due to the bulk expansion in the periphery of specific T cells against known tumor 
antigens in anti-CTLA-4 treated patients [53–55]. Of note, an increase in absolute 
Figure 1. 
Effect of immune checkpoint inhibition on effector T cells.
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lymphocyte count (ALC) was shown to correlate with enhanced overall survival 
and response to ipilimumab in several studies [56–59].
The distribution of the TCR repertoire may be described by different metrics. For 
example, TCR richness invoke the number of unique T cell clones while its evenness 
refers to the frequency of their distribution. Some studies reported an increase in the 
richness of the TCR repertoire under anti-CTLA-4 therapy [60, 61]. On the contrary, 
the evenness of the TCR repertoire under anti-CTLA-4 therapy is comparatively less 
impacted [60, 62, 63]. This increase in richness of the TCR repertoire under the effect 
of anti-CTLA-4 therapy is indicative of unleashed T-cell priming possibly allowing 
for enhanced tumor immune control through the promotion of new anti-tumor T 
cells responses [64]. However, in a study on metastatic melanoma and prostate cancer, 
it has been shown that enhanced clinical outcomes under CTLA-4 blockade are asso-
ciated with less clonotype loss and on-treatment stability of existing high-frequency 
TCR clonotypes [61]. These findings suggest that response to anti-CTLA-4 treatment 
occurs despite the remodeling of the peripheral TCR repertoire rather than as a result 
of it. In Figure 1 we illustrate the dynamics of intra-tumoral effector T cells that are 
shown to correlate with anti-CTLA-4 treatment outcome.
3. Effect of immune checkpoint blockade on immune suppressive T cells
3.1 Effect of PD-1 blockade on immune suppressive T cells
Regulatory T cells (Tregs), an immunosuppressive subset of T cells, are known 
to be closely involved in the regulation of the immune responses to cancer [65–67]. 
The tumor-infiltrating subsets of Tregs are characterized by their high surface 
expression of PD-1 [68–70] and the PD-1/PD-L1 axis is known to modulate Tregs 
function via cell-intrinsic pathways. For example, the blocking of PD-1 in animal 
models reduced the immunosuppressive function of Tregs and declined their 
expression in the TME [71, 72]. Moreover, studies on murine models have shown 
that PD-1/PD-L1 pathway mediates the conversion of CD4+ Th1 effector T cells into 
induced Foxp3+ Tregs (iTregs) [73, 74]. Conversely, certain preclinical studies show 
that anti-PD-1 therapy is associated with an increase rather than a decrease in Tregs 
infiltration in the TME [24, 75]. The proliferation of Tregs under anti-PD-1 therapy 
could be explained by a treatment-induced reversal of the exhausted state of PD-1Hi 
in the TME [76, 77]. The expansion of Tregs upon blockade of PD-1/PD-L1 axis has 
been observed at the tumor level as well as in the peripheral blood. One particular 
study showed that patients with gastric adenocarcinoma responding to anti-PD-1 
displayed an on-treatment decrease in intra-tumoral Tregs, whereas non-respond-
ers had post-treatment tumor biopsies exhibiting an infiltration of highly prolifera-
tive effector Tregs (Foxp-3hi/CD45− CD4+) [78]. This suggests that on-treatment 
changes in intra-tumoral T reg infiltration could be a relevant dynamic parameter 
to account for in predicting anti-PD-1/PD-L1 treatment response. The predictive 
insight provided by the on-treatment dynamics of circulating Tregs under PD-1/
PD-L1 blockade has also been investigated. In a study conducted on melanoma 
patients exposed to nivolumab, an expansion of circulating Tregs under therapy was 
shown to positively correlate with treatment benefit [79]. These observations sug-
gest that Tregs dynamics under anti-Pd-1 therapy may contribute predictive insight 
into treatment benefit when monitored both in the TME and in the periphery.
Interestingly, another immunosuppressive CD4+ T cell subset found to be 
regulated by anti-PD-1 therapy has been recently identified. These cells known as 
4PD-1Hi express high levels of PD-1 while lacking Foxp-3 expression [80]. Also, these 
4PD-1Hi cells were shown to accumulate in the tumor and to inhibit T cells effector 
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function. Therefore, 4PD1Hi cells are considered as a marker of tumor progression. 
Anti-PD-1 treatment was shown to reduce the proliferation of 4PD-1Hi cells, whereas 
anti-CTLA-4 treatment showed an exactly opposite effect on these cells. In line with 
this interesting observation, the downregulation of 4PD-1Hi cells under anti-PD-1 
treatment was further documented as a biomarker of treatment response under 
anti-PD-1 pembrolizumab antibody in a melanoma patient cohort. In addition, some 
preclinical studies support the fact that anti-PD-1 therapy can induce the expansion 
of specific CD8+ T cells immunosuppressive subsets [30]. Indeed, a recent study 
showed that PD-1 blockade in sub-optimally primed T cell conditions supported the 
proliferation of dysfunctional immunosuppressive CD8+ T cells expressing PD-1 and 
high levels of CD38 and this effect was associated with treatment failure and tumor 
resistance in cancer patients [81]. The dynamics of these T cell subsets under treat-
ment may therefore provide valuable predictive information, pending the validation 
of these candidate biomarkers in larger scale studies. The proposed mechanisms of 
anti-PD-1 action on Tregs subsets are summarized in Figure 2.
3.2 Effect of CTLA-4 blockade on regulatory T cells
Several observations suggest the action of anti-CTLA-4 on Tregs to be key in 
mediating treatment effects on the tumor. Indeed, some studies involving murine 
tumor models reported anti-CTLA-4 treatment to simultaneously induce an 
increased expansion of peripheral Tregs and a decreased expansion of intra-tumoral 
Tregs [82–84]. This dual action of anti-CTLA-4 on Tregs proliferation could be due to 
the higher expression of CTLA-4 on exhausted tumor-infiltrating Tregs, where their 
decline under treatment is suggested to be mediated by a distinct Fc-gamma receptor 
dependent mechanism of anti-body-mediated cell-mediated cytotoxicity (ADCC) 
Figure 2. 
Effect of immune checkpoint inhibition on immune suppressive T cells.
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[85]. This feature was suggested to play a key role in tumor control under CTLA-4 
blockade since it has been demonstrated that an on-treatment increase in intra-
tumoral Teffs: Tregs ratio stands as the correlate of an optimal treatment response 
[82, 83, 86, 87]. Moreover, in another study in different murine models, the therapeu-
tic activity of ipilimumab was found to essentially rely on this Fc-dependent Tregs 
depletion and not on the checkpoint inhibitor action of the drug [88]. However, there 
is noticeable inconsistencies in observed Tregs dynamics under CTLA-4 blockade in 
humans. Indeed, certain studies document a remarkable expansion of Tregs in the 
peripheral blood of patients treated with anti-CTLA-4 [51, 89–91], while other stud-
ies report a declined or unchanging frequency of peripheral Tregs during this therapy 
[37, 49, 92]. In addition, the ability of the peripheral Tregs dynamics to predict a 
treatment response to anti-CTLA-4 treatment is also quite unclear. For example, their 
change in frequency is found to correlate both negatively [93] and positively [90] 
with anti-CTLA-4 treatment benefit. Yet some other studies show no correlation at 
all between the change in Tregs frequency and a treatment response to anti-CTLA-4 
therapy [56, 94, 95]. Observations of the intra-tumoral Tregs dynamics under anti-
CTLA-4 is also inconclusive. A contradictory effect is put forth by a cohort on region-
ally advanced melanoma patients treated with 2 neoadjuvant doses of ipilimumab. 
This study reported a reversed association between the change in intra-tumoral Tregs 
frequency and treatment benefit [90]. Similarly, another study reported a marked 
decline in intra-tumoral Tregs levels in melanoma patients responding to ipilimumab 
compared to non-responding ones [96]. On the contrary, two other studies report 
increasing frequencies of Tregs in biopsies of patients undergoing anti-CTLA-4 
therapy [13, 32]. It is interesting to note that the accumulation of Tregs within the 
tumors upon CTLA-4 blockade may be induced by a feedback loop triggered by a 
successful cytotoxic T cell response [97]. This may account for the positive correlation 
between the intra-tumoral levels of Tregs and patient long-term survival as reported 
by some studies involving solid tumors [98, 99]. These observations nonetheless 
suggest that Tregs dynamics under CTLA-4 treatment, in the TME and possibly in 
the periphery, should be accounted for when monitoring for treatment effects. The 
depletion of intra-tumoral Tregs under CTLA-4 blockade is illustrated in Figure 2.
3.3 Effect of PD-1 and CTLA-4 blockade on myeloid cell compartment
Monocytes, macrophages and dendritic cells are involved in antigen presenta-
tion and T cells priming and thereby serve as a bridge between the innate and 
adaptive immune response. However, chronic inflammation arising due to cancer 
disturbs the myeloid cell line maturation process, leading to the generation of 
myeloid derived suppressor cells [MDSCs] and tumor-associated macrophages 
[TAMs], that are both suppressors of the anti-tumor immune response [100]. These 
tumor associated monocytes and macrophages are known to display a wide variety 
of phenotypes with both pro-inflammatory [M1] and immunosuppressive [M2] 
functions [101]. Likewise, several studies on animal models have found that treat-
ment with ICIs has the ability of bringing about a spectacular transformation of the 
intra-tumoral myeloid cell compartment from an immunosuppressive configura-
tion to a more pro-inflammatory one [102, 103]. It has been suggested that the 
increased INF-γ secretion by renewed T cells would possibly indirectly mediate this 
myeloid cell reprogramming in the TME under immune checkpoint therapy [102]. 
Also, it was observed that dual PD-1 and CTLA-4 blockade induces an increase in 
intra-tumoral pro-inflammatory macrophages, as shown in animal models [104]. 
In addition, potential direct mechanisms of regulation of MDSCs by anti-PD-1 or 
anti-CTLA-4 treatment were also identified. As an example, an induced expres-
sion of CTLA-4 on monocyte-derived dendritic cells [mDCs] acts as a negative 
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regulator of mDCs-associated cytokine secretion and antigen-specific CD4+ T cell 
proliferation [105]. Moreover, subsets of intra-tumoral MDSCs that express PD-1 
and CTLA-4 are found to display decreased arginase 1 expression and activity upon 
anti-CTLA-4 or anti-PD-1 treatment in mice [106]. In murine models, it has been 
shown that arginase 1 impairs T cells functions and contributes to immune evasion 
[107]. Furthermore, it has been recently reported that anti-PD-1 therapy was able to 
prevent the block in myeloid cell lineage maturation, thereby allowing the myeloid 
precursors to maturate into effector macrophages and dendritic cells contributing 
favorably to the anti-tumoral immune response [108].
A decline in circulating MDSCs under anti-CTLA-4 is found to correlate with 
patient outcome in several studies [37, 90, 109, 110], although this association is 
not universally reported [111]. Moreover, these studies showed discordant observa-
tions regarding the dynamics and predictive value of the major MDSCs subsets 
(monocytic MDSCs (mo-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs) 
subsets) [112]. In addition, several studies showed that anti-PD-1 treatment had no 
effect on the level of circulating mo-MDSC and PMN-MDSC subsets [9, 113, 114]. Yet 
a particular study revealed a prominent restructuration of the myeloid compartment 
after initiation of anti-PD-1 therapy in metastatic melanoma patients when studied 
Figure 3. 
Effect of PD-1 and CTLA-4 blockade on myeloid cells.
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under the lens of high dimensional single cell analysis platforms [113]. Therefore, the 
ability to monitor the evolution of myeloid cells under immune checkpoint blockade 
appears to be of great predictive value, considering the important role that this cell 
compartment possibly plays in the modulation of the anti-tumoral immune response 
by either promoting or preventing the effector T cells response observed upon these 
therapies. One example of the described mechanisms of anti-PD-1 and anti-CTLA-4 
effect on myeloid cells compartment is illustrated in Figure 3.
4.  Dynamic predictive and prognostic soluble biomarkers in cancer 
immunotherapy
In the subsections below, we will focus on blood-based candidate biomarkers 
that can be utilized as predictive or prognostic markers in cancer immunotherapy.
4.1 Blood cell counts/ratios, C-reactive protein and lactate dehydrogenase
Changes in the blood cell counts and their ratios including neutrophils, lym-
phocytes, neutrophil to lymphocyte ratio as well as C-Reactive Protein (CRP) and 
Lactate Dehydrogenase (LDH) have been reported as prognostic/predictive out-
come markers for immunotherapy [2]. Several studies have shown that low neu-
trophils and high lymphocytes are associated with overall survival (OS) in cancer 
patients [58, 115, 116]. For example, melanoma patients on nivolumab treatment 
having absolute lymphocyte counts of >1000/μL and absolute neutrophil count of 
<4000/μL were observed to have better overall survival [115]. On the other hand, 
pre-treatment neutrophil-to-lymphocyte ratio (NLR) and derived NLR (dNLR) 
can also serve as an index of the systemic inflammatory response and therefore 
considered as useful indicators of response in immunotherapy. Pre-treatment NLR/
dNLR levels and survival association studies in advanced cancers including mela-
noma, non-small-cell lung cancer (NSCLC) and genitourinary have reported that 
high pre-treatment NLR and dNLR levels are associated with poor progression free 
survival (PFS)/OS with increased risks of death in immunotherapy treated patients 
indicating their usefulness as predictive and prognostic biomarkers [117–120].
CRP is an inflammatory marker that induces the expression of acute-phase 
proteins such as neutrophils and has been correlated with poor prognosis in several 
cancers [121, 122]. With regards to immunotherapy, post treatment increased 
CRP levels have been associated with inflammation, disease progression and in 
some cases immune-related adverse events. On the other hand, low CRP levels 
post immunotherapies have been associated with better antitumor response/ 
survival [93, 123].
LDH is a final enzyme in the glycolysis pathway that catalyzes the interconver-
sion of pyruvate and lactate. In cancers, high levels of LDH leads to increased 
utilization of glycolysis as their energy requirement in the microenvironment [124]. 
Studies have confirmed that LDH is a significant negative prognostic factor for 
immunotherapy treated stage 4 melanoma patients [125]. Elevated baseline LDH 
in melanoma and lung cancer patients treated with pembrolizumab/nivolumab is 
associated with poor OS and higher risk of death [126–128]. Similar results have 
been reported for advanced esophageal squamous cell carcinoma patients treated 
with the anti-PD-1 immune checkpoint inhibitor camrelizumab where elevated 
LDH levels were found to correlate with poor OS [129].
The fact that blood cell counts/ratios, CRP and LDH tests are performed as part 
of a routine diagnosis and also are highly assessable/measurable at various treat-
ment timelines in patients making them attractive dynamic biomarkers.
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4.2 Soluble immune checkpoint inhibitors
Soluble forms of immune checkpoints (sICs) are shed in the plasma/serum 
and have been associated with modulation of the immune system by affecting the 
binding capacity of immunotherapeutic drugs and thus influencing the efficiency 
of immune system. Studies have demonstrated that sICs can serve as markers for 
prognosis, response to treatment and overall response rate (ORR) in immunother-
apy treated patients [130]. In addition to this, these markers can also be important 
for prediction of immune related adverse events which is an area poorly explored 
with respect to these biomarkers. Here, in this sub-section, we will discuss sICs 
evidenced in literature as prognostic and predictive markers in ICIs treatment.
4.2.1 Soluble immune inhibitory markers
4.2.1.1 Soluble PD-1, PDL-1 and PDL-2
sPD-1 has been documented to inhibit all three PD-L1/PD-1 interactions: PD-L1/
CD80, PD-L1/PD-1, and PDL2/PD-1 [131]. Researchers have demonstrated that 
expressed sPD-1 blocks PD-L1/PD-1 interactions that can lead to inhibition of 
tumor growth via various mechanisms including blockade of PD-L1 on tumor cells, 
upregulation of CD8+ T cells, reduction in the expression of IL-10, increased pro-
duction of inducible nitric oxide synthase, TNF-α and IFN-γ and enhancement of 
the immune response through interaction with immune cells [132–134]. sPD-1 has 
been reported as a modulator of immune response during ICIs treatment in serum 
of cancer patients. A study on 22 NSCLC patients observed that sPD-1 decreased 
significantly in clinically responding patients during Nivolumab treatment. In 
addition to this, patients with performance status of 0 had a decreased sPD-1 
during treatment and these patients were found to have better immune fitness 
with low levels of immunosuppression [135]. Similarly, a study on 177 unresectable 
metastatic melanoma patients treated with anti-PD-1 showed interesting results. 
High pre-treatment serum concentrations of PD-1 and PD-L1 were correlated with 
poor prognosis and survival. The authors postulated that circulating serum PD-1 
molecules might be directly targeted by therapeutic anti-PD-1 antibodies and this 
interaction might impair the effectiveness of anti-PD-1 therapy via neutralization. 
It is possible that this is a tumor escape mechanism that facilitates poor outcome. 
Thus, quantification of circulating PD-1 and PD-L1 molecules can translate into 
prognostic and predictive factors in immunotherapy treated patients [136].
sPD-L1 is produced by tumor cells/activated mature DCs and is known to have 
structural similarities to mPD-L1 [137]. It has been postulated that sPD-L1 has the 
capability to exert a competing effect against anti-PD-L1 drugs. A study by Gong et 
al. reported that NSCLC patients who were refractory to ICIs treatment secreted 
a sPD-L1 variant (without the transmembrane domain) in serum and this variant 
competed, bound and then inhibited the activity of immunotherapeutic drug in such 
patients [138]. This is a critical finding as it gives evidence on the dynamic role of 
sPD-L1 and its utility as a biomarker of response in immunotherapy. Furthermore, 
studies on various cancers have also reported on this aspect. For example, a study on 
ipilimumab treated melanoma patients showed that patients with high pre-treatment 
sPD-L1 levels showed poor prognosis and disease progression [139]. This is an 
interesting observation and sheds light on the dynamic nature of this biomarker. 
Similarly, two studies on NSCLC have documented that high levels of sPD-L1 cor-
related with poor prognosis, OS, and abdominal metastasis [140, 141]. However, 
to date no correlation of sPD-L1 with tissue PD-L1expression has been reported 
indicating the dynamic nature of secreted PD-L1 that is distinct from tissue PD-L1. 
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Several published studies evidence consistent data on its utility as a monitoring tool 
to test the efficacy of ICIs as a prognostic biomarker. Further studies with systematic 
uniform methodologies may allow better understanding of sPD-L1 as an effective 
tool for patient stratification with regards to anti-PD-1 therapy benefit.
sPD-L2 is a splice variant protein product that lacks transmembrane domain and 
is secreted into the blood. Distinct expression pattern of PD-L2 variants in leuko-
cytes of distinct cellular status have been observed suggesting that modulation of 
sPD-L2 expression may have an influence on the outcome of the immune response 
[142]. However, limited data on sPD-L2 as an immune related biomarker is available. 
A study by Zizari et al., on NSCLC patients treated with Nivolumab showed that 
sPD-L2 was dynamically modulated during ICIs treatment. The concentrations of 
sPD-L2 were found to be significantly lower in responding patients. In addition to 
this, soluble mediators including low PD-L1, CD137, Tim-3 and BTLA-4 in combina-
tion with low sPD-L2 are associated with favorable clinical response indicating that 
sPD-L2 works in synergy with other molecules to modulate the immune response. 
This allows understanding on the dynamic interaction of soluble immune modula-
tors as useful biomarkers of response [135]. In addition to response prediction, a 
study on NSCLC patients treated with Nivolumab reported interesting results with 
respect to immune related adverse events. Low sPD-L2 concentration at diagnosis 
as well as in pre-treatment samples was found to be associated with occurrence of 
immune grade 3–4 toxicity indicating that sPD-L2 can also serve as potential predic-
tive biomarker for immune related adverse events in ICIs treated patients [143].
4.2.1.2 Soluble CTLA-4, TIM-3 and LAG-3
The major source of sCTLA-4 is Tregs, monocytes and immature DCs [144]. 
sCTLA-4 has been reported in several studies as a plausible marker for response in 
ICIs treatment. For example, in melanoma patients treated with ipilimumab, high 
pre-treatment expression of sCTLA-4 was associated with response to treatment 
and longer OS [145]. Another study on metastatic melanoma patients treated with 
ipilimumab showed similar results with high levels of sCTLA-4 at baseline associated 
with disease responsiveness and survival. Interestingly, the study observed that in 
responding patients, sCTLA-4 concentration increased with subsequent treatment 
cycles while in progressing patients, sCTLA-4 decreased subsequently indicating 
that sCTLA-4 can serve as a valuable dynamic marker for treatment monitoring. In 
addition to this, it was also observed that patients with high pre-treatment sCTLA-4 
were at a higher risk of developing immune related adverse events providing further 
insight into its utility as a biomarker of response/adverse event monitoring [146]. 
However, in different cancers, its utility may be distinct based on its interaction with 
other molecules and subsequent immune modulation. For example, a recent study 
on NSCLC patients treated with nivolumab showed that lower concentration of 
sCTLA-4 at 3 months of clinical evaluation was associated with response. In addi-
tion to this, patients with performance status of 0 consistently maintained a lower 
expression of sCTLA-4 from the time of treatment initiation until 3 months of clini-
cal evaluation indicating that sCTLA-4 can be an indicator of immune fitness in ICIs 
treated patients [135]. It is postulated that during ICIs treatment, sCTLA-4 might be 
involved in enhancing the ability of host cytotoxic T cells to attack tumor cells and 
thereby enhancing the antitumor effect of immunotherapy.
sTIM-3 secreted in blood lacks mucin and transmembrane domains. It is postulated 
that sTIM-3 is shed from the cell surface due to metalloproteinase-dependent cleavage 
and may serve as a decoy receptor for TIM-3 ligands thereby interfering with the inhibi-
tory function of TIM-3 [147]. However, the exact function of sTIM-3 is still unknown. 
A study on plasma levels of sTIM-3 in ICIs treated patients observed that NSCLC 
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patients treated with nivolumab had a lower level of sTIM-3 at three months of clinical 
evaluation and this correlated with the response and longer survival of the patient [135]. 
Though, the study does give an indication of sTIM-3 as biomarker of response, further 
studies are needed to understand its dynamic nature in ICIs treatment.
sLAG-3 plays a role in immune pathways and has been associated as a Th1 activ-
ity marker in serum. sLAG-3 has been reported to bind to MHC class II and induce 
maturation of dendritic cells thereby facilitating attack on tumor cells [148, 149]. This 
makes sLAG-3 an attractive biomarker in ICIs treatment. Though several studies on 
LAG-3 and cellular response has been documented, there is paucity of data on the util-
ity of sLAG-3 in serum of ICIs treated patients. A study on nivolumab treated NSCLC 
patients reported that sLAG-3 was significantly increased during treatment and this 
increase was retained in non-responding patients. In addition to sLAG-3, other soluble 
mediators including sPD-1 and sPDL-2 were also increased in these patients indicating 
the dynamic interactive nature of LAG-3 and its role as predictive marker [135].
4.2.1.3 Soluble IDO, CD163 and NKG2DL
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that acts as an immune check-
point and inhibits T-cell proliferation by starving the cells from tryptophan (trp) in 
order to sensitize them to apoptosis [150]. IDO facilitates tumor immune escape and 
several preclinical studies have associated IDO activity with immunotherapeutic 
resistance [151]. A study on nivolumab treated NSCLC patients found that lower 
baseline level of IDO activity in serum was significantly associated with better PFS/
OS while higher levels were associated with early progression indicating that high 
serum levels can serve as early marker of response/indicator of resistance to anti-PD-1 
treatment [152]. On the other hand, a larger study on 27 NSCLC patients treated with 
nivolumab indicated the dynamic nature of sIDO at baseline, 2 months and at disease 
progression. The study aimed to evaluate the dynamic nature of IDO as a predictor of 
response. Interestingly, the authors observed that at baseline, IDO activity was higher 
in responding patients than non-responding patients. However, in patients who did not 
benefit from immunotherapy, a statistically significant increase was observed between 
baseline sample and sample taken at the time to disease progression indicating the 
potential utility of IDO as therapeutic resistance marker to anti-PD-1 treatment [153].
CD163 is the hemoglobin/haptoglobin complex scavenger receptor expressed 
exclusively on circulating monocytes/tissue macrophages. It is involved in anti-
inflammatory functions associated with macrophages and therefore plays an impor-
tant role in suppressing anti-tumor immune responses [154]. sCD163 is secreted 
in plasma via proteolytic shedding and is considered a specific marker for TAM. 
To demonstrate the utility of sCD163 as a marker of response in immunotherapy, 
Fujimura et al. conducted a study on 59 cases of advanced cutaneous melanoma and 
16 cases of advanced mucosal melanoma treated with nivolumab. It was observed 
that in advanced cutaneous melanoma group, sCD163 was significantly increased 
at 6 weeks of treatment in the response group as compared to non-response group 
indicating that sCD163 is an early marker of response in nivolumab treated patients 
[155]. On the other hand, another study by the same group determined the utility of 
sCD163 as predictor of immune related adverse events (irAE) in nivolumab treated 
advanced melanoma patients. It was observed that at day 42 of treatment, the abso-
lute value of sCD163 significantly increased in patients with adverse nivolumab-
induced, immune-related events indicating that sCD163 can also serve as a valuable 
predictor of irAEs in immunotherapy [155]. However, due to limited published 
data, further studies will provide a better understanding on this marker.
NKG2D is an activating immunoreceptor of cytotoxic lymphocytes and is 
expressed on T, NK, and NKT cells. NKG2D has eight ligands including MIC (MICA 
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and MICB) or ULBP (ULBP1, ULBP2, ULBP3, ULBP4, RAET1G, and RAET1L) 
family. These NKG2D ligands are absent on normal cells but are usually overexpressed 
on tumor cells. Soluble NKG2D ligands (sNKG2DLs) are generated by proteolytic 
shedding of tumor cells which boosts tumor immune escape by binding and subse-
quent endocytosis/degradation of NKG2D receptor on NK/T cells thus suppressing 
antitumor immune responses [156, 157]. Various sNKG2DLs have been studied as 
predictive biomarkers of response in immunotherapy. A study in melanoma patients 
by Maccalli et al., showed that absence of soluble sMICB, sULBP-1 and sULBP-2 in 
baseline serum of anti-PD-1 treated patients correlated with improved survival while 
detectable levels of these molecules was correlated with poor survival [158]. Similarly, 
another study by the same group on melanoma patients showed that elevated sULBP2 
in early-stage patients on ICIs treatment was a strong indicator of poor prognosis 
indicating the clinical usefulness of sULBP2 as a distinguishing marker for classifying 
prognosis in early- and late-stage melanoma patients on treatment [156].
4.2.2 Soluble immune stimulatory markers
4.2.2.1 Soluble CD27 and CD28
CD27 is expressed in lymphocytes and is activated by its ligand, CD70, which 
is a member of the tumor necrosis factor receptor superfamily. Upon binding of 
CD70 to CD27, soluble CD27 (sCD27) is cleaved off by metalloproteinases and is 
secreted in serum, plasma, and urine samples. Studies have suggested that changes 
in sCD27 levels reflect the activity of systemic immunity [159]. In various hemato-
logical malignancies increased levels of sCD27 have been reported to correlate with 
poor prognosis [160]. A study on 16 advanced lung cancer patients on anti-PD-1 
treatment were tested for their pretreatment sCD27 levels and correlated with their 
response patterns. It was observed that a sCD27 level was higher in patients with 
longer survival and in such patients the duration of treatment was shorter. The 
authors suggested that sCD27 levels can serve as prognostic marker for predicting 
effectiveness of ICIs in advanced lung cancer [161].
CD28 is a second messenger of T cell activation and is a critical immune checkpoint 
for recognition of dendritic cells by T cells. Previous studies have suggested that PD-1 
antibodies rely on the activation of the CD28/B7 pathway to rescue the depletion CD8+ 
T cells and then achieve anti-tumor effects [162]. Soluble sCD28 has been reported 
as a modulator of T cells for proliferation and is therefore considered an attractive 
biomarker of response to ICIs treatment [163]. Recently, a study on 44 patients with 
various cancers (lung, tongue, esophageal and nasopharyngeal, colorectal, cholangio-
carcinoma, gastric, duodenal adenocarcinoma, renal cell carcinoma, hepatocellular 
carcinoma, and malignant melanoma) on anti-PD-1 treatment were tested for serum 
CD28 along with other soluble markers. It was observed that patients with higher 
baseline sCD28 expression had a longer PFS and responded better to treatment than 
non-responsive patients [164]. This dynamic change in sCD28 during treatment gives 
a credible index in terms of its predictive efficiency as a promising response marker. 
However, larger studies on this aspect are needed to understand the role of this marker.
5. Conclusion
Using ICIs have shown promising effect in treating cancers. However, only small 
group of patients are responsive to this treatment strategy. Tumor resistance to the 
immune response can be mediated by the involvement of several immunological 
pathways. In this chapter, we reviewed the different immunological pathways that 
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can be modulated by immune checkpoint blockade and more specifically PD-1 and 
CTLA-4 inhibitors. We have summarized all the findings obtained in pre-clinical and 
clinical trials reporting an impact of anti-PD-1 and anti-CTLA-4 on intra-tumoral 
and peripheral immune response. Interestingly, the study of the dynamics of the 
immune system under CTLA-4 and PD-1 inhibitors shows a noticeable distinction in 
their regulatory mode of action on the anti-tumoral and peripheral immune response. 
Moreover, the findings discussed in this chapter show that CTLA-4 and PD-1 inhibi-
tors do not only restore intra-tumoral effector T cells activity upon exhaustion but are 
also able to induce a consequential remodeling of the tumor microenvironment as well 
as the systemic immune response. Indeed, the field of immunological liquid biomark-
ers is fast evolving with many novel predictive and prognostics markers gaining 
attention. Though, liquid biopsies have many advantages including minimal invasive-
ness, longitudinal monitoring and simultaneous parallel testing with highly sensitive/
specific high throughput applications. Although several studies state the utility of 
soluble ICIs markers, it is observed that the characteristic feature of these markers is to 
modulate the immune response in synergy with each other. This makes them attractive 
candidates as up and down regulation of a combination of markers can allow better 
understanding of the immune modulatory and dynamic nature of soluble immune 
molecules involved in ICIs treatment. However, there are several limitations that need 
to be addressed for these markers. Mainly, standardization of sampling/measurement 
techniques as well as larger validation studies are required to verify the utility of these 
markers as promising tools to guide and monitor treatment decisions in ICIs treated 
patients. Finally, identification of dynamic biomarkers for prediction of ICIs tumor 
control and for monitoring of patient response under treatment is gaining considerable 
knowledge through recent technologies including proteomics and transcriptomics. 
Progress along this approach is critical to build reasoning for novel therapeutic combi-
nations and to set forth a more personalized cancer immunotherapeutic strategy.
Acronyms and abbreviations
ICI immune checkpoint inhibitors
PD-L1 programmed death-ligand 1
PD-1 programmed death- 1
CTLA-4 cytotoxic T-lymphocyte-associated protein 4
TCR T cell receptor
TME tumor microenvironment
TIM-3 T-cell immunoglobulin and mucin-domain containing-3
LAG-3 lymphocyte-activation gene-3
TIGIT T cell immunoreceptor with Ig and ITIM domains
Tex exhausted T cells
Teff effector T cells
ALC absolute lymphocyte count
MDSCs myeloid derived suppressor cells
TAM tumor-associated macrophages





dNLR derived Neutrophil-to-lymphocyte ratio
NSCLC non-small-cell lung cancer
PFS progression free survival
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NK natural killer
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